Menu

Thomas Frieden, Former CDC Chief, Arrested on Sexual Abuse Charges

A woman told police in July that Frieden groped her in his Brooklyn apartment in October 2017.

Aug 24, 2018
Sukanya Charuchandra
Thomas Frieden
WIKIMEDIA COMMONS, Centers for Disease Control

Thomas Frieden, previously the New York City Health Commissioner and director of the Centers for Disease Control and Prevention, surrendered to the New York Police Department’s Special Victims Unit this morning (August 24) on charges of sexual harassment. 

According to The Washington Post, a New York police spokeswoman says, “He was arrested for forcible touching, for sexual abuse and harassment, for touching her buttocks without permission.” Frieden will likely face a second-degree charge of harassment, third-degree count of sex abuse, and one count of forcible touching in the Brooklyn Criminal Court, reports CNN.

The woman in question was known to Frieden and the incident happened in his Brooklyn Heights apartment on October 20, 2017. She filed a report in July. 

Former President Barack Obama appointed Frieden as head of the Centers for Disease Control and Prevention (CDC) in 2009. He led the organization for eight years until January 2017 when President Donald Trump’s administration took charge. At the CDC, Frieden shaped strategies to address several high-profile health emergencies, including the 2009 H1N1 pandemic and the 2014 Ebola outbreak. 

During his tenure from 2002 to 2009 at New York City’s Department of Health and Mental Hygiene under then-Mayor Michael Bloomberg, Frieden banned smoking in workplaces and the use of artificial trans fats in restaurant food. 

According to STAT News, Frieden founded the global health organization Resolve to Save Lives with the help of a $225-million donation from Bloomberg Philanthropies, the Chan Zuckerberg Initiative, and the Bill and Melinda Gates Foundation. 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.